Cleansing Statement Sydney, 20 November 2026: Australian clinical-stage biotechnology company Noxopharm Limited (ASX:NOX) (Noxopharm or the Company) has today issued 1,240,351 new fully paid shares in lieu of Directors’ Fees, as approved by the shareholders of the Company at the 2026 Annual...
Cleansing Statement
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Noxopharm Ltd. has issued a Cleansing Statement regarding the issuance of new shares. The company issued new shares in lieu of Directors’ Fees, as approved by shareholders at the recent Annual General Meeting. This notice is provided under the Corporations Act, confirming compliance with relevant provisions. Noxopharm assures that there is no excluded information that needs to be disclosed at this time.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Noxopharm
- Application for quotation of securities - NOX
- Proposed issue of securities - NOX
- Notice of Extraordinary General Meeting/Proxy Form
- Results of Meeting
- Noxopharm 2026 AGM Corporate Presentation
Later from Noxopharm
All Noxopharm news releasesFollow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm